SCHEMBL23328675

SCHEMBL23328675

COS(=O)(=O)CNC(=O)Nc1ccc(N(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
RAB9A P51151 6/20 0.56
NPC1 O15118 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
NOX1 Q9Y5S8 4/20 0.56
TP53 P04637 2/20 0.56
ESR2 Q92731 1/20 0.56
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
HPGD P15428 2/20 0.52
HDAC3 O15379 2/20 0.51
HDAC4 P56524 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC7 Q8WUI4 2/20 0.51
HDAC2 Q92769 2/20 0.51
HDAC10 Q969S8 2/20 0.51
HDAC11 Q96DB2 2/20 0.51
HDAC8 Q9BY41 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23328674 0.84 HDAC3 (0.58) MAPTRAB9ANPC1SMN1; SMN2NOX1
SCHEMBL23328728 0.82 RAB9A (0.53) MAPTRAB9ANPC1SMN1; SMN2TP53
SCHEMBL23329078 0.82 SAE1 (0.56) MAPTRAB9ANPC1SMN1; SMN2CA12
SCHEMBL23328374 0.79 MEN1 (0.59) MAPTRAB9ACA12CA1CA2
SCHEMBL23329072 0.79 CA12 (0.53) MAPTRAB9ANPC1SMN1; SMN2CA12
SCHEMBL16363832 0.77 NOX1 (0.63) MAPTRAB9ANPC1SMN1; SMN2NOX1
SCHEMBL29663991 0.76 RAB9A (0.76) MAPTRAB9ANPC1SMN1; SMN2NOX1
SCHEMBL28800706 0.74 HDAC3 (0.57) MAPTRAB9ANPC1SMN1; SMN2NOX1
SCHEMBL14423985 0.74 MAPT (0.74) MAPTRAB9ANPC1SMN1; SMN2NOX1
SCHEMBL16364130 0.73 HDAC3 (0.56) MAPTRAB9ANPC1SMN1; SMN2NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 MAPT 2612/4885RAB9A 1656/4885NPC1 407/4885
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS ARF1, ARL1, TLR1 MAPT 2612/4885RAB9A 1656/4885NPC1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.